Estimated legacy effects from simulated post-trial data were less biased than from combined trial/post-trial data.
| Field | Value | Language |
| dc.contributor.author | Zhu, Lin | |
| dc.contributor.author | Bell, Katy J.L. | |
| dc.contributor.author | Hayen, Andrew | |
| dc.date.accessioned | 2021-04-14T06:53:11Z | |
| dc.date.available | 2021-04-14T06:53:11Z | |
| dc.date.issued | 2019 | en |
| dc.identifier.uri | https://hdl.handle.net/2123/24923 | |
| dc.description.abstract | “Legacy effects” describe the phenomena where treatment effects are apparent during the post-trial period that are not attributable to the direct effects observed within the trial. We investigate different approaches to analysis of trial and extended follow-up data for the evaluation of legacy effects. We conducted a simulation to compare three approaches, which differed in terms of the time period and selection of trial participants included in the analysis. | en |
| dc.language.iso | en | en |
| dc.publisher | Elsevier | en |
| dc.relation.ispartof | Journal of Clinical Epidemiology | en |
| dc.rights | Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 | en |
| dc.subject | Legacy effects | en |
| dc.subject | randomised control trial | en |
| dc.subject | Post-trial follow-up | en |
| dc.subject | cardiovascular disease | en |
| dc.title | Estimated legacy effects from simulated post-trial data were less biased than from combined trial/post-trial data. | en |
| dc.type | Article | en |
| dc.subject.asrc | 1102 Cardiorespiratory Medicine and Haematology | en |
| dc.subject.asrc | 1117 Public Health and Health Services | en |
| dc.identifier.doi | 10.1016/j.jclinepi.2019.05.010 | |
| dc.relation.nhmrc | 1104136 | |
| usyd.faculty | SeS faculties schools::Faculty of Medicine and Health::Sydney School of Public Health | en |
| usyd.citation.volume | 114 | en |
| usyd.citation.spage | 30 | en |
| usyd.citation.epage | 37 | en |
| workflow.metadata.only | No | en |
Associated file/s
Associated collections